{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:50:00Z","timestamp":1787496600921,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117035","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:31:26Z","timestamp":1731029486000},"page":"117035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Rational design and synthesis of novel N-benzylindole-based epalrestat analogs as selective aldose reductase inhibitors: An unexpected discovery of a new glucose-lowering agent (AK-4) acting as a mitochondrial uncoupler"],"prefix":"10.1016","volume":"281","author":[{"given":"Antonios","family":"Kousaxidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-7266","authenticated-orcid":false,"given":"Paolo","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Kovacikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Stefek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthi","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-0015","authenticated-orcid":false,"given":"Ioannis","family":"Nicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117035_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112742","article-title":"Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus","volume":"207","author":"Kousaxidis","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib2","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.3390\/ijms22126403","article-title":"Role of insulin in health and disease: an update","volume":"22","author":"Rahman","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.117035_bib3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.dsx.2018.10.008","article-title":"Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention","volume":"13","author":"Tan","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ejmech.2024.117035_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2024.117035_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00228-017-2326-z","article-title":"Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients","volume":"73","author":"Pariente","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117035_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdiacomp.2014.01.007","article-title":"The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: a retrospective cohort study","volume":"28","author":"Morgan","year":"2014","journal-title":"J. Diabetes Complications"},{"key":"10.1016\/j.ejmech.2024.117035_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/medicina58101475","article-title":"An update on the current and emerging use of thiazolidinediones for type 2 diabetes","volume":"58","author":"Giglio","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ejmech.2024.117035_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.31083\/j.fbs1601005","article-title":"Mitochondrial dysfunction as a factor of energy metabolism disorders in type 2 diabetes mellitus","volume":"16","author":"Blagov","year":"2024","journal-title":"Front. Biosci. (Schol. Ed.)"},{"key":"10.1016\/j.ejmech.2024.117035_bib9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.117035_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116567","article-title":"A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha\/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties","volume":"275","author":"Laghezza","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib11","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2337\/db19-0589","article-title":"Mitochondrial uncoupling coordinated with PDH activation safely ameliorates hyperglycemia via promoting glucose oxidation","volume":"68","author":"Jiang","year":"2019","journal-title":"J. Diabetes"},{"key":"10.1016\/j.ejmech.2024.117035_bib12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm.3699","article-title":"Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice","volume":"20","author":"Tao","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.117035_bib13","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/molecules25081987","article-title":"Type 2 diabetes mellitus: a review of multi-target drugs","volume":"25","author":"Artasensi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.117035_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200043","article-title":"Identification of 9H-purin-6-amine derivatives as novel aldose reductase inhibitors for the treatment of diabetic complications","volume":"355","author":"Zhu","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2024.117035_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175191","article-title":"Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer","volume":"931","author":"Bailly","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117035_bib16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2174\/1871527320666210303111939","article-title":"Pharmacological treatment of diabetic peripheral neuropathy: an update","volume":"21","author":"Rafiullah","year":"2022","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.ejmech.2024.117035_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.hlife.2023.12.002","article-title":"Aldo-keto reductase 1B: much learned, much more to do","volume":"2","author":"Zhao","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.ejmech.2024.117035_bib18","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1016\/j.bmcl.2018.10.024","article-title":"An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications","volume":"28","author":"Maccari","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117035_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/molecules26020330","article-title":"In search for multi-target ligands as potential agents for diabetes mellitus and its complications-A structure-activity relationship study on inhibitors of aldose reductase and protein tyrosine phosphatase 1B","volume":"26","author":"Ottan\u00e0","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.117035_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115270","article-title":"Designed multiple ligands for the treatment of type 2 diabetes mellitus and its complications: discovery of (5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)alkanoic acids active as novel dual-targeted PTP1B\/AKR1B1 inhibitors","volume":"252","author":"Maccari","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib21","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1016\/j.febslet.2013.09.031","article-title":"Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111)","volume":"587","author":"Zhang","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2024.117035_bib22","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4155\/fmc-2020-0032","article-title":"Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications","volume":"12","author":"Kumar","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejmech.2013.10.043","article-title":"Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs)","volume":"71","author":"Reddy","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1021\/jm201243p","article-title":"Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry","volume":"55","author":"Mendgen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib25","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/acs.chemrestox.5b00247","article-title":"Systematic evaluation of the metabolism and toxicity of thiazolidinone and imidazolidinone heterocycles","volume":"28","author":"Tang","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117035_bib26","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/molecules26102867","article-title":"Development of novel indole-based bifunctional aldose reductase inhibitors\/antioxidants as promising drugs for the treatment of diabetic complications","volume":"26","author":"Kovacikova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.117035_bib27","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/jm5015814","article-title":"Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold","volume":"58","author":"Stefek","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/acs.jmedchem.9b01747","article-title":"Development of novel oxotriazinoindole inhibitors of aldose reductase: isosteric sulfur\/oxygen replacement in the thioxotriazinoindole cemtirestat markedly improved inhibition selectivity","volume":"63","author":"Hlav\u00e1\u010d","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib29","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/jm030762f","article-title":"Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives","volume":"46","author":"Da Settimo","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib30","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1021\/jm0492094","article-title":"Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications","volume":"48","author":"Van Zandt","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115575","article-title":"Design synthesis and evaluation of novel aldose reductase inhibitors: the case of indolyl-sulfonyl-phenols","volume":"28","author":"Koutsopoulos","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.febslet.2011.11.023","article-title":"The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase","volume":"586","author":"Zheng","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2024.117035_bib33","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.1021\/acs.jmedchem.8b01453","article-title":"Halogens in protein-ligand binding mechanism: a structural perspective","volume":"62","author":"Shinada","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib34","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/cb400526n","article-title":"Modulation of aldose reductase inhibition by halogen bond tuning","volume":"8","author":"Fanfrl\u00edk","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.117035_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jmb.2005.10.067","article-title":"High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group","volume":"356","author":"Steuber","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.117035_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134116","article-title":"A molecular hybridization approach for the design of selective aldose reductase (ALR2) inhibitors and exploration of their activities against protein tyrosine phosphatase 1B (PTP1B)","volume":"1271","author":"Kousaxidis","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2024.117035_bib37","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib38","doi-asserted-by":"crossref","first-page":"18087","DOI":"10.1021\/acs.jafc.3c00765","article-title":"Applications of bioisosteres in the design of biologically active compounds","volume":"71","author":"Meanwell","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib39","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1021\/acs.jmedchem.2c02015","article-title":"\"Magic chloro\": profound effects of the chlorine atom in drug discovery","volume":"66","author":"Chiodi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ardp.19973300506","article-title":"Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azolyl-1-phenylmethyl)-1H-indoles as inhibitors of P450 arom","volume":"330","author":"Le Borgne","year":"1997","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2024.117035_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0223-5234(02)00005-3","article-title":"Synthesis and antifungal activity of new 1-halogenobenzyl-3-imidazolylmethylindole derivatives","volume":"38","author":"Na","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib42","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1080\/00397911.2010.515352","article-title":"L-Proline-Catalyzed synthesis of novel 5-(1H-Indol-3-yl-methylene)-thiazolidine-2,4-dione derivatives as potential antihyperglycemic agents","volume":"41","author":"Riyaz","year":"2011","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2024.117035_bib43","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0968-0896(01)00366-2","article-title":"Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones","volume":"10","author":"Bruno","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib44","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.bmc.2005.04.058","article-title":"5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents","volume":"13","author":"Ottan\u00e0","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib45","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1248\/cpb.39.1440","article-title":"Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds","volume":"39","author":"Momose","year":"1991","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2024.117035_bib46","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.tetlet.2007.02.029","article-title":"A mild hydrolysis of esters mediated by lithium salts","volume":"48","author":"Mattsson","year":"2007","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2024.117035_bib47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/1062936X.2015.1074939","article-title":"Prediction of enzyme inhibition and mode of inhibitory action based on calculation of distances between hydrogen bond donor\/acceptor groups of the molecule and docking analysis: an application on the discovery of novel effective PTP1B inhibitors","volume":"26","author":"Eleftheriou","year":"2015","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2024.117035_bib48","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1016\/j.bbagen.2013.01.017","article-title":"The insulin-mimetic effect of Morin: a promising molecule in diabetes treatment","volume":"1830","author":"Paoli","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2024.117035_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12013-019-00882-5","article-title":"Selective covalent inhibition of \"allosteric Cys121\" distort the binding of PTP1B enzyme: a novel therapeutic approach for cancer treatment","volume":"77","author":"Khan","year":"2019","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2024.117035_bib50","doi-asserted-by":"crossref","first-page":"33396","DOI":"10.1074\/jbc.M705224200","article-title":"Chemical knockdown of protein-tyrosine phosphatase 1B by 1,2-naphthoquinone through covalent modification causes persistent transactivation of epidermal growth factor receptor","volume":"282","author":"Iwamoto","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib51","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/acs.biochem.7b00151","article-title":"Covalent allosteric inactivation of protein tyrosine phosphatase 1B (PTP1B) by an inhibitor-electrophile conjugate","volume":"56","author":"Punthasee","year":"2017","journal-title":"Biochem."},{"key":"10.1016\/j.ejmech.2024.117035_bib52","doi-asserted-by":"crossref","first-page":"7704","DOI":"10.1021\/bi047417s","article-title":"Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue","volume":"44","author":"Hansen","year":"2005","journal-title":"Biochem."},{"key":"10.1016\/j.ejmech.2024.117035_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2005.03.033","article-title":"Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?","volume":"70","author":"Feinstein","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117035_bib54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbabio.2004.12.005","article-title":"Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier","volume":"1707","author":"Hildyard","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2024.117035_bib55","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1073\/pnas.1303360110","article-title":"Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier","volume":"110","author":"Divakaruni","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.117035_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061551","article-title":"Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins","volume":"8","author":"Colca","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.117035_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174627","article-title":"5-Benzylidene, 5-benzyl, and 3-benzylthiazolidine-2,4-diones as potential inhibitors of the mitochondrial pyruvate carrier: effects on mitochondrial functions and survival in Drosophila melanogaster","volume":"913","author":"Touaibia","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117035_bib58","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1021\/acs.jmedchem.2c02093","article-title":"A new antidiabetic agent showing short- and long-term effects due to peroxisome proliferator-activated receptor alpha\/gamma dual agonism and mitochondrial pyruvate carrier inhibition","volume":"66","author":"Laghezza","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.2003.049478","article-title":"Mitochondrial formation of reactive oxygen species","volume":"552","author":"Turrens","year":"2003","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejmech.2024.117035_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/dmd.121.000552","article-title":"Evaluation of ADMET predictor in early discovery drug metabolism and pharmacokinetics Project work","volume":"50","author":"Sohlenius Sternbeck","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2024.117035_bib61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2024.117035_bib62","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib63","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/pharmaceutics15041095","article-title":"In silico analyses of a promising drug candidate for the treatment of amyotrophic lateral sclerosis targeting superoxide dismutase I protein","volume":"15","author":"Coutinho Pereira","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2024.117035_bib64","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1592\/phco.28.5.646","article-title":"Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy","volume":"28","author":"Ramirez","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2024.117035_bib65","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4014\/jmb.2101.01002","article-title":"Neuroprotective effect of epalrestat on hydrogen peroxide-induced neurodegeneration in SH-SY5Y cellular model","volume":"31","author":"Lingappa","year":"2021","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejmech.2024.117035_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1454770","article-title":"Drug transport by red blood cells","volume":"15","author":"Biagiotti","year":"2024","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejmech.2024.117035_bib67","first-page":"e2763","article-title":"Microbial mutagenicity assay: ames test","volume":"8","author":"Vijay","year":"2018","journal-title":"Bio Protoc"},{"key":"10.1016\/j.ejmech.2024.117035_bib68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40360-021-00519-5","article-title":"Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19","volume":"22","author":"Aminpour","year":"2021","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117035_bib69","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3390\/pharmaceutics15071941","article-title":"Therapeutic potential and predictive pharmaceutical modeling of stilbenes in cannabis sativa","volume":"15","author":"O'Croinin","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2024.117035_bib70","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jat.4409","article-title":"Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues","volume":"43","author":"Liu","year":"2023","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117035_bib71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/cpdd.1347","article-title":"Bioequivalence study of epalrestat for healthy Chinese subjects","volume":"13","author":"Yang","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2024.117035_bib72","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1021\/acs.jmedchem.5b00201","article-title":"Volume of distribution in drug design","volume":"58","author":"Smith","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib73","doi-asserted-by":"crossref","first-page":"32784","DOI":"10.1074\/jbc.M606873200","article-title":"Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics","volume":"281","author":"Ala","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117035_bib74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijbiomac.2021.02.189","article-title":"Lsc\u03b2 and lsc\u03b3, two novel levansucrases of Pseudomonas syringae pv. actinidiae biovar 3, the causal agent of bacterial canker of kiwifruit, show different enzymatic properties","volume":"179","author":"Luti","year":"2021","journal-title":"Int. J. Biol. Macromol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T03:58:11Z","timestamp":1734235091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424009176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":74,"alternative-id":["S0223523424009176"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117035","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design and synthesis of novel N-benzylindole-based epalrestat analogs as selective aldose reductase inhibitors: An unexpected discovery of a new glucose-lowering agent (AK-4) acting as a mitochondrial uncoupler","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117035"}}